| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Atropine sulfate monohydrate (Sulfatropinol; Tropintran; Atropette; Corbella), the sulfate salt and hydrated form of atropine, is a competitive and broad-spectrum antagonist of the muscarinic acetylcholine receptors. It has been approved for decreasing the production of saliva and secretions of the airway prior to surgery.
| ln Vitro |
The relaxation of human pulmonary veins caused by ACh is inhibited by Atropine sulfate monohydrate (Tropine tropate; 1 μM; pulmonary veins and arteries) [4].
|
|---|---|
| ln Vivo |
Anesthesia-induced cardiac arrhythmias are suppressed by Atropine sulfate monohydrate (Tropine tropate; 10 mg/kg; intraperitoneal injection; once over 40 minutes; Peromyscus sp.) [2].
|
| Animal Protocol |
Animal/Disease Models: White-footed mice (Peromyscus sp.)[2]
Doses: 10 mg/kg Route of Administration: intraperitoneal (ip)injection; once, for 40 minutes Experimental Results: Increased heart rate was a decrease in cardiac arrhythmia. |
| References |
[1]. McBrien NA, et, al. How does atropine exert its anti-myopia effects? Ophthalmic Physiol Opt. 2013 May;33(3):373-8.
[2]. Morhardt JE. Heart rates, breathing rates and the effects of atropine and acetylcholine on white-footed mice (Peromyscus sp.) during daily torpor. Comp Biochem Physiol. 1970 Mar 15;33(2):441-57. [3]. Carr BJ, et, al. Myopia-Inhibiting Concentrations of Muscarinic Receptor Antagonists Block Activation of Alpha2A-Adrenoceptors In Vitro. Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2778-2791. [4]. Walch L, et, al. Evidence for a M(1) muscarinic receptor on the endothelium of human pulmonary veins. Br J Pharmacol. 2000 May;130(1):73-8. |
| Molecular Formula |
2(C17H23NO3).H2O.H2SO4
|
|
|---|---|---|
| Molecular Weight |
694.83
|
|
| CAS # |
5908-99-6
|
|
| Related CAS # |
Atropine-d5;Atropine;51-55-8;Atropine sulfate;55-48-1
|
|
| SMILES |
S(=O)(=O)(O[H])O[H].O(C(C([H])(C1C([H])=C([H])C([H])=C([H])C=1[H])C([H])([H])O[H])=O)C1([H])C([H])([H])[C@@]2([H])C([H])([H])C([H])([H])[C@@]([H])(C1([H])[H])N2C([H])([H])[H].O(C(C([H])(C1C([H])=C([H])C([H])=C([H])C=1[H])C([H])([H])O[H])=O)C1([H])C([H])([H])[C@@]2([H])C([H])([H])C([H])([H])[C@@]([H])(C1([H])[H])N2C([H])([H])[H].O([H])[H]
|
|
| InChi Key |
PVGPXGKNDGTPTD-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C17H23NO3.H2O4S.H2O/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12;1-5(2,3)4;/h2-6,13-16,19H,7-11H2,1H3;(H2,1,2,3,4);1H2
|
|
| Chemical Name |
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate;sulfuric acid, hydrate
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (287.83 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4392 mL | 7.1960 mL | 14.3920 mL | |
| 5 mM | 0.2878 mL | 1.4392 mL | 2.8784 mL | |
| 10 mM | 0.1439 mL | 0.7196 mL | 1.4392 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA